Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a global structural heart innovation company focused on improving patient lives through medical technologies. The company has been a leader in its field for over six decades, building on its founder's vision to use engineering for heart disease. Edwards Lifesciences develops both surgical and transcatheter therapies. Its portfolio includes repair and replacement technologies for aortic, mitral, tricuspid, and pulmonic heart valves, offering treatment options for diverse and complex patient needs. The company's strategy emphasizes transformative product innovation, high-quality clinical evidence to support approvals and adoption, and comprehensive support for patient outcomes. Cardiovascular disease is the leading cause of death globally and the top disease in healthcare spending in nearly every country. In the U.S., one cardiovascular patient dies every 34 seconds. This disease is progressive and often affects heart structure. Edwards Lifesciences aims to transform patient care through earlier diagnosis, routine treatment, increased longevity, and improved quality of life. Future growth opportunities include solutions for patients with both valvular and non-valvular structural heart disease, such as heart failure, which can result from conditions like aortic stenosis, mitral and tricuspid regurgitation, and aortic regurgitation. The company's medical technologies are designed to address individual patient needs based on disease process, comorbidities, and health status.